Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Ther...
August 28 2019 - 04:01PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ocular and rare
diseases, today announced that 24-week data from the first cohort
of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022
intravitreal injection gene therapy in wet AMD will be presented at
the Retina Subspecialty Day Program of the American Academy of
Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA on
Friday, October 11, 2019.
“Wet AMD is an aggressive disease that often requires frequent
anti-VEGF injections over the long-term in order to reduce vision
loss,” said Aaron Osborne, MBBS, MRCOphth, chief medical officer of
Adverum Biotechnologies. “ADVM-022 is administered utilizing a
single, standard-of-care intravitreal injection, which we believe
has the potential to significantly reduce treatment burden and
improve real-world vision outcomes for patients with wet AMD. We
look forward to presenting 24-week data from the first cohort of
patients in the OPTIC trial at the upcoming AAO meeting.”
Event: 2019 American Academy of Ophthalmology
Podium Presentation: 24-week Results of Phase 1
Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular
AMD (OPTIC Trial) Abstract #:
30062032Section: Section VIII: Late Breaking
Developments, Part IDate: October 11,
2019Time: 4:26 p.m. – 4:31 p.m.
PTLocation: Moscone Center, San Francisco,
CASpeaker: Szilard Kiss, M.D., director of
clinical research in the Department of Ophthalmology at Weill
Cornell Medical College
About Adverum Biotechnologies, Inc.Adverum is a
clinical-stage gene therapy company targeting unmet medical needs
in ocular and rare diseases. Adverum develops gene therapy product
candidates designed to provide durable efficacy by inducing
sustained expression of a therapeutic protein. Adverum’s core
capabilities include clinical development, novel vector discovery
and in-house manufacturing expertise, specifically in scalable
process development, assay development, and current Good
Manufacturing Practices quality control. For more information,
please visit www.adverum.com.
Investor and Media Inquiries:
Investors:
Myesha Lacy
Investor Relations and Corporate Communications
mlacy@adverum.com
650-304-3892
Media:
Joshua R. Mansbach
Solebury Trout
jmansbach@troutgroup.com
646-378-2964
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2023 to Mar 2024